What do you get when you combine Obamacare with an expected explosion in the use of pricey drugs and the rapid aging of the Baby Boomer population? The answer, courtesy of the Centers for Medicare & Medicaid Services (CMS) today: national health expenditures that are projected to grow an average of 5.8% a year for […]

Two of the most anticipated new heart drugs to be launched in recent years have been priced well above analyst expectations, fuelling the debate about whether modern medicines cost too much. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk […]

TARRYTOWN, N.Y. and PARIS, July 24, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as an adjunct to […]

The U.S. Food and Drug Administration approved a potent new cholesterol-lowering drug from Sanofi SA and Regeneron Pharmaceuticals Inc on Friday but limited its approved use to patients with a hereditary form of the condition and those with cardiovascular disease. The FDA ruling came just hours after European regulators recommended approval for broader use of […]

WASHINGTON, July 24, 2015 /PRNewswire-USNewswire/ — Despite claims that tens of millions of Americans could be eligible for treatment with a new class of cholesterol-lowering medications, called PCSK9 inhibitors, the fact is these new medicines will not replace existing treatment options and will address a significant unmet medical need in a small subset of people. […]